Key result
Neurexan significantly attenuated stress-induced increases in frontotemporal beta2 EEG power during a cognitive task compared to placebo in healthy volunteers.
Why the study?
Neurexan is used for stress-related symptoms, but its efficacy on stress-induced changes of brainwave frequencies required investigation.
Does Neurexan reduce stress-induced changes in spectral EEG power in healthy volunteers?
RCT (n=30)
Double-blind
Randomized
No
Does Neurexan reduce stress-induced changes in spectral EEG power in healthy volunteers?
In healthy volunteers, a single dose of Neurexan attenuated stress-induced increases in frontotemporal beta2 EEG power, suggesting a potential acute stress-reducing neurophysiological effect.
Neurexan attenuates stress-induced frontotemporal beta2 elevation; extends mechanistic RCT evidence in healthy volunteers but leaves clinical adoption open.
Neurexan is a multicomponent natural medicinal product used for stress-related symptoms such as nervous restlessness and insomnia. The present study investigated the efficacy of Neurexan on stress-induced changes of brainwave frequencies using quantitative analysis of spectral EEG power. Thirty healthy male and female volunteers were tested in a randomized, placebo controlled cross-over trial under conditions of relaxation and experimental stress-in- duction. Recording of the EEG was performed over four hours after drug administration. Data was analyzed using the proprietary fast dynamic EEG technology Neurocode-Tracking. Quantitative EEG revealed a task dependent increase of beta2 power as a surrogate parameter of stress induced anxiety. The elevated frontotemporal beta2 power was ameliorated by intake of Neurexan during the second and third hour after administration. This indicates that Neurexan is effectively helping subjects to better cope with task-related stress situations.
No takes yet. Share an insight, caveat, or question.
Wilfried Dimpfel (2019) conducted an RCT in Healthy volunteers (experimental stress) (n=30). Neurexan vs. Placebo was evaluated on Stress-induced changes of spectral EEG power (frontotemporal beta2 power) during a Concentration Performance Test (p=<0.05). Neurexan significantly attenuated stress-induced increases in frontotemporal beta2 EEG power during a cognitive task compared to placebo in healthy volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: